EcoDrugPlus

Serine/threonine-Protein Kinase D3-Like

Ensembl ID : ENSCVAG00000018649
Gene Symbol: LOC107098152
2 Cross references
207 Possible Orthologues:

Serpin Family C Member 1

Ensembl ID : ENSCVAG00000021609
Gene Symbol: SERPINC1
3 Cross references
202 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSCVAG00000000289
Gene Symbol: LOC107104179
2 Cross references
357 Possible Orthologues:

Si:dkey-211g8.6

Ensembl ID : ENSCVAG00000017210
Gene Symbol: SI:DKEY-211G8.6
1 Cross references
319 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSCVAG00000002545
Gene Symbol: SIGMAR1
3 Cross references
205 Possible Orthologues:

Sirtuin 1

Ensembl ID : ENSCVAG00000005781
Gene Symbol: SIRT1
3 Cross references
158 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSCVAG00000011446
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha B-Like

Ensembl ID : ENSCVAG00000015521
Gene Symbol: LOC107097019
3 Cross references
245 Possible Orthologues:

Sodium Channel Protein Type 5 Subunit Alpha-Like

Ensembl ID : ENSCVAG00000022766
Gene Symbol: LOC107081157
2 Cross references
246 Possible Orthologues:

Sodium Channel Protein Type 8 Subunit Alpha-Like

Ensembl ID : ENSCVAG00000012101
Gene Symbol: LOC107092636
2 Cross references
150 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSCVAG00000007353
Gene Symbol: SCN4A
3 Cross references
187 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSCVAG00000001487
Gene Symbol: SCN8A
3 Cross references
219 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).